Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

• Main Authors: Alexander Egeberg (Author), Jason E. Hawkes (Author), Najwa Somani (Author), Russel Burge (Author), Kyoungah See (Author), Gaia Gallo (Author), Missy McKean-Matthews (Author), Melinda Gooderham (Author), George Han (Author), April Armstrong (Author)
• Formato: Livro
• Publicado em: Adis, Springer Healthcare, 2024-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat with non-systemic therapies, this post hoc analysis f...